The Filing Desk

Acadia Pharmaceuticals vs Spyre Therapeutics

Acadia Pharmaceuticals ACAD · Spyre Therapeutics SYRE · Pharmaceuticals

Side by side

Acadia PharmaceuticalsSpyre Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1.1B$0M
Revenue growth11.9%—
Revenue growth a year, last 5 years19.4%—
Gross margin91.7%—
Operating margin9.8%—
Net margin36.5%—
Free cash flow$105M—
Free cash flow margin9.8%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count2.1%—
Last close$18.75$104.00
P/E at the last close8.8×—
Insider trades, last 12 monthssold $2.8 millionsold $435.7 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Acadia PharmaceuticalsSpyre Therapeutics
Operating margin
Percent of revenue
Acadia PharmaceuticalsSpyre Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Acadia PharmaceuticalsSpyre Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Acadia Pharmaceuticals and Spyre Therapeutics pages.